Aberrant EZHIP expression drives tumorigenesis in osteosarcoma
Open Access
- 22 July 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Abstract
Osteosarcomas (OS) are aggressive bone tumors known for their extensive structural variations and rare recurrent oncogenic driver mutations. In this study, we identify ectopic expression of the oncohistone-mimic EZHIP in 20% of patients across two independent OS cohorts. We demonstrate that reduced deposition of the repressive H3K27me3 mark correlates with poor histological response to neoadjuvant therapy, serving as a predictor of patient outcomes. Through gain- and loss-of-function experiments, we provide functional evidence of the oncogenic activity of EZHIP in enhancing the aggressive characteristics of OS both in vitro and in vivo. EZHIP-induced epigenetic reprogramming reactivates developmental pathways and impedes the differentiation of mesenchymal progenitors, pushing them towards smooth muscle lineage commitment at the cost of other fates. Targeting residual H3K27me3 with EZH2 inhibitors may offer therapeutic benefit in EZHIP-expressing OS. Our findings highlight EZHIP expression as a prevalent driver in OS, offering insights into its pathogenic mechanisms and potential therapeutic strategies for this debilitating cancer.Keywords
Funding Information
- Terry Fox Foundation
This publication has 69 references indexed in Scilit:
- Distinct genomic landscapes in radiation‐associated angiosarcoma compared with other radiation‐associated sarcoma histologiesThe Journal of Pathology, 2023
- Notch Signaling in Osteogenesis, Osteoclastogenesis, and AngiogenesisThe American Journal of Pathology, 2019
- Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomasActa Neuropathologica, 2018
- Identification of a novel, recurrent MBTD1‐CXorf67 fusion in low‐grade endometrial stromal sarcomaInternational Journal of Cancer, 2013
- Transforming Growth Factor-β and Notch Signaling Mediate Stem Cell Differentiation into Smooth Muscle CellsStem Cells, 2010
- Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cellsBone, 2009
- Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumorsCancer, 2008
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancersMolecular Carcinogenesis, 2008
- Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapyCancer, 1982
- Characterization of non‐producer human cells induced by kirsten sarcoma virusInternational Journal of Cancer, 1975